← Back to Clinical Trials
Recruiting NCT07262190

NCT07262190 NavSTAR Implementation Effectiveness Trial Across a Health System

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07262190
Status Recruiting
Phase
Sponsor Friends Research Institute, Inc.
Condition Opioid Use Disorder
Study Type INTERVENTIONAL
Enrollment 720 participants
Start Date 2025-10-27
Primary Completion 2029-01-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
NavSTAR (Philly adaptation)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 720 participants in total. It began in 2025-10-27 with a primary completion date of 2029-01-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Patient Navigation (PN) interventions following hospitalization can improve outcomes for people with opioid use disorder treatment. Delivering PN interventions on a wide scale requires many resources and coordination across institutions. This will use an evidence-based process to find solutions to these significant barriers by engaging community, hospital, and patient partners. This study is being conducted to learn more about how to implement NavSTAR, a patient navigation intervention for people with opioid use disorder, across a health system. The research team showed in a previous study with 400 participants that NavSTAR significantly increased entry into opioid use disorder treatment, reduced readmissions to the hospital, and was highly cost- effective compared to treatment as usual. This study will first pilot NavSTAR with 32 patient participants across 4 hospitals in the City of Philadelphia. Then, a large trial with 720 patient participants will be conducted to see if people who need the intervention are reached, and a sustainable plan will be created to continue the intervention after the grant award period.

Eligibility Criteria

Inclusion Criteria: 1. age 18 or older; 2. current DSM-5 criteria for moderate to severe OUD; 3. willing and able to provide informed consent in English. Exclusion Criteria: 1. enrollment in OUD treatment 30-days prior to hospitalization; 2. residency outside the City of Philadelphia; 3. pregnancy; 4. planned discharge to a long-term inpatient care facility (e.g., hospice); 5. hospitalization for a suicide attempt.

Contact & Investigator

Central Contact

Karen Alexander, PhD

✉ kalexander@friendsresearch.org

📞 2673983560

Frequently Asked Questions

Who can join the NCT07262190 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Opioid Use Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07262190 currently recruiting?

Yes, NCT07262190 is actively recruiting participants. Contact the research team at kalexander@friendsresearch.org for enrollment information.

Where is the NCT07262190 trial being conducted?

This trial is being conducted at Philadelphia, United States.

Who is sponsoring the NCT07262190 clinical trial?

NCT07262190 is sponsored by Friends Research Institute, Inc.. The trial plans to enroll 720 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology